# Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

> **NCT02361346** · PHASE1,PHASE2 · TERMINATED · sponsor: **Molecular Templates, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Non-Hodgkin's B-cell Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Small Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Blood Cancer
- Hematological Malignancy

## Interventions

- **DRUG:** MT-3724 Phase 1
- **DRUG:** MT-3724 Phase 2

## Key facts

- **NCT ID:** NCT02361346
- **Lead sponsor:** Molecular Templates, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2021-03-22
- **Final completion:** 2021-03-22
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Sponsor decision following clinical hold
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02361346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02361346, "Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02361346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*